NeuPath Health (NPTH) Q2 2025 earnings summary

Executive summary

• Achieved record Q2 total revenue of $23.6 million, up 25% year-over-year, and $43.0 million for the six months, up 18% year-over-year.

• Adjusted EBITDA reached $2.2 million for Q2, up 69% year-over-year, marking the 26th consecutive quarter of positive Adjusted EBITDA.

• Improved capacity utilization to 84% in Q2 and 79% for the six months, driven by stronger revenues and clinic optimization.

• Substantial uptake of Arthrosamid® since its March launch contributed to growth.

Financial highlights

• Clinic revenue was $22.2 million in Q2, up from $17.3 million year-over-year, with a material one-time payment boosting results.

• Non-clinic revenue was $1.4 million in Q2, slightly down from $1.6 million year-over-year.

• Gross margin was 19.8% in Q2, compared to 20.0% in the prior year, with the increase driven by positive reimbursement adjustments and fluoroscopy revenues.

• Net and comprehensive income for Q2 was $342,000, with Adjusted EBITDA at $2.2 million.

Outlook and guidance

• Management expects continued growth in the second half of 2025, supported by further investments in the clinic network and strategic opportunities.

• Focus remains on optimizing clinic footprint and enhancing patient outcomes.